Clinical Efficacy of Modified Xiaofengsan and Its Effect on Cytokines in Persistent Asthma Patients with Wind-asthma Pattern

Lin JIA; Lei WU; Bo-lin LI; Li-ying WEI

doi:10.13422/j.cnki.syfjx.20190119

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Modified Xiaofengsan and Its Effect on Cytokines in Persistent Asthma Patients with Wind-asthma Pattern

Classic Prescriptions | 更新时间：2021-02-09

- Clinical Efficacy of Modified Xiaofengsan and Its Effect on Cytokines in Persistent Asthma Patients with Wind-asthma Pattern
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 4, Pages: 70-74(2019)
- 作者机构：
  
  河北省中医院，石家庄　 050031
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20190119
  CLC： R22;R242;R2-031;R287
- Received：17 July 2018，
  
  Published Online：17 October 2018，
  
  Published：20 February 2019
- 稿件说明：
移动端阅览
Lin JIA, Lei WU, Bo-lin LI, et al. Clinical Efficacy of Modified Xiaofengsan and Its Effect on Cytokines in Persistent Asthma Patients with Wind-asthma Pattern[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(4): 70-74.
DOI：

Lin JIA, Lei WU, Bo-lin LI, et al. Clinical Efficacy of Modified Xiaofengsan and Its Effect on Cytokines in Persistent Asthma Patients with Wind-asthma Pattern[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(4): 70-74. DOI： 10.13422/j.cnki.syfjx.20190119.

摘要

目的：

观测加味消风散治疗慢性持续期支气管哮喘风哮证的临床疗效及对炎症因子的影响。

方法：

将120例符合纳入标准的慢性持续期哮喘患者随机分为对照组和治疗组，各60例。对照组60例，单用布地奈德福莫特罗粉吸入剂(160 μg/4.5 μg)，2吸/次，

bid

。治疗组予加味消风散，日1剂，并联合布地奈德福莫特罗粉吸入剂(160 μg/4.5 μg)治疗。两组疗程均为1个月。观察两组患者临床疗效，治疗前后及治疗结束3个月后哮喘控制测试(asthma control test，ACT)评分表的得分情况以及治疗前后半年内哮喘平均急性发作次数，测定两组患者治疗前后第1秒用力呼气量占预计值百分比(percentage of forced expiratory volume in first second and its predicted value，FEV

%)，PEF变异率(variety ratio of peak expiratory flow，PEF)，外周血嗜酸性粒细胞(eosinophilic granulocyte，EOS)计数和血清白细胞介素-4(interleukin-4，IL-4)，白细胞介素-6(interleukin-6，IL-6)，白细胞介素-13(interleukin-13，IL-13)水平。并对两组患者进行安全性评价。

结果：

治疗组总有效率高于对照组(

0.05)；治疗后及治疗结束3个月后ACT评分比较，治疗组高于对照组(

0.05)；治疗后治疗组FEV

%高于对照组(

0.05)；治疗后治疗组急性发作次数，PEF变异率，外周血EOS计数和血清IL-4，IL-6，IL-13水平低于对照组(

0.05)。

结论：

加味消风散联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘风哮证可有效缓解症状，提高临床疗效，改善肺功能，降低血清炎症因子水平，改善气道慢性炎症状态。

Abstract

Objective:

To observe the clinical efficacy of modified Xiaofengsan and its effect on cytokines in persistent asthma patients with wind-asthma pattern.

Method:

The 120 eligible patients with chronic and persistent asthma were randomly divided into control group (60 cases) and treatment group (60 cases). Patients in control group received the budesonide/formoterol (160 μg/4.5 μg

2 inhales/time

bid

). Patients in treatment group additionally received the modified Xiaofengsan combined with budesonide/formoterol (160 μg/4.5 μg). The treatment course was 1 month in both groups. The clinical efficacy of the two groups was observed. Before and 3 months after treatment

asthma control test (ACT) and the average times of acute exacerbation in 6 months before and after treatment between two groups were observed; percentage of forced expiratory volume in first second and its predicted value (FEV

variety ratio of Peak expiratory flow (PEF)

eosinophilic granulocyte (EOS) count in peripheral blood and the levels of interleukin-4(IL-4)

interleukin-6(IL-6) and interleukin-13(IL-13) in serum were measured before and after treatment respectively. In addition

the safety of the two groups was evaluated.

Result:

The total effective rate of the treatment group was higher than that of the control group (

0.05). The levels of ACT value and FEV

% in treatment group were higher(

0.05)

while the average times of acute exacerbation

PEF variety ratio

EOS count in peripheral blood

L-4

IL-6 and IL-13 in serum were lower(

0.05) than those in control group after treatment. There was no significant difference in incidence of the adverse reactions.

Conclusion:

Modified Xiaofengsan combined with budesonide/formoterol could relieve symptoms of asthma

improve pulmonary function and lower the levels of IL-4

IL-6 and IL-13 in serum.

关键词

Keywords

references

Lang D M . Severe asthma：epidemiology，burden of illness，and heterogeneity [J]. Allergy Asthma Proces , 2015 , 36 ( 6 ): 418 - 424 .

中华医学会呼吸病学分会哮喘学组，中华医学会全科医学分会．中国支气管哮喘防治指南(基层版) [J]. 中华结核和呼吸杂志， 2013 , 36 ( 5 ): 331 - 336 .

中华人民共和国卫生部．中药新药临床研究指导原则 [M]. 北京：中国医药科技出版社， 2002 ： 61 .

国家中医药管理局．中医病证诊断疗效标准 [M]. 南京：南京大学出版社， 1994 ： 6 .

Garcia-Marcos L , Castro-Rodriguez J A , Weinmayr G , et al . Influence of mediterranean diet on asthma in children：a systematic review and Meta-analysis [J]. Pediatr Allergy Immunol , 2013 , 24 ( 4 ): 330 - 338 .

To Y , Dohi M , Tanaka R , et al . Early in interleukin-4-dependent response can induce airway hyperreactivity before development of airway inflammation in a mouse model of asthma [J]. Lab Invest , 2001 , 81 ( 10 ): 1385 - 1396 .

Lloyd C M , Hessel E M. Functions of T cells in asthma：more than just T(H)2 cells [J]. Nat Rev Immunol , 2010 , 10 ( 12 ): 838 - 848 .

Sanderson C J . Interleukin-5，eosinophils and disease [J]. Blood , 1992 , 79 ( 12 ): 3101 - 3109 .

Heijink I H , Vellenga E , Borger P , et al . Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and-independent mechanisms in freshly isolated human T cells [J]. Immunology , 2002 , 107 ( 3 ): 316 - 324 .

David M , Walter J J , Mcintire G B , et al . Critical role for IL-13 in the development of allergen-induced airway hyperreactivity [J]. J Immunol , 2001 , 167 ( 8 ): 4668 - 4675 .

杨玉萍，晁恩祥．国医大师晁恩祥教授从风论治呼吸疾病理论 [J]. 中华中医药杂志， 2014 , 29 ( 12 ): 3702 - 3704 .

王晓玲．蝎僵龙解痉平喘汤治疗支气管哮喘34例疗效观察 [J]. 河北中医， 2005 , 27 ( 11 ): 830 - 831 .

朱良春．虫类药的应用 [M]. 北京：人民卫生出版社， 2011 ： 83 - 84 .

黄伯舜．虫类中药临床应用心得 [J]. 中国中药杂志， 2005 , 30 ( 17 ): 1369 - 1371 .

喻静．僵蚕的临床应用及现代药理研究 [J]. 中国中医药咨讯， 2010 , 2 ( 7 ): 185 - 186 .

赵清，霍利琴，贾天柱．不同炮制方法对僵蚕体外抗氧化活性及其对酪氨酸酶抑制能力的影响 [J]. 中国实验方剂学杂志， 2014 , 20 ( 3 ): 17 - 23 .

徐树楠，张美玉，王永梅，等．蝉蜕镇咳、祛痰、平喘作用的药理研究 [J]. 中国药理学通报， 2007 , 23 ( 12 ): 1678 - 1679 .

李璐，王永香，王秀海，等．地龙及其复方治疗糖尿病肾病的机制研究进展 [J]. 中国实验方剂学杂志， 2017 , 23 ( 7 ): 227 - 234 .

傅炜昕，董占双，李铁英，等．免疫活性地龙肽的制备及其对小鼠NK细胞活性的影响 [J]. 中国医科大学学报， 2007 , 36 ( 6 ): 650 - 652 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guben Fangxiao decoction Regulates Expression of CGRP /ILC2 and GABA in Human Bronchial Epithelial Cells Stimulated with IL-4 Combined with IL-13

Yiqi Wenyang Huwei Decoction in Treatment of Bronchial Asthma in Rats by Regulating TGF-β₁/Smad3 Signaling Pathway

Traditional Chinese Medicine Regulates Oxidative Stress-related Signaling Pathways to Prevent and Treat Bronchial Asthma： A Review

Yiqi Wenyang Huwei Decoction Regulates PI3K/Akt/mTOR Pathway to Treat Bronchial Asthma in Rats

Effect of Shufeng Tongluo Prescription on Eotaxin and CCR3 Protein Expression and ERK Phosphorylation Level of Asthma Mice

Related Author

OU Weiying

YUAN Xuejing

JI Jianjian

SU Xiaopu

TANG Wei

YE Chao

YU Qiangqiang

SUN Peng

Related Institution

The First Clinical Medical College of Nanjing University of Chinese Medicine

Affiliated Hospital of Nanjing University of Chinese Medicine

Affiliated Hospital of Jiangxi University of Chinese Medicine

Jiangxi University of Chinese Medicine

Henan Provincial People's Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰